Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous azithromycin-induced ototoxicity.

E D Bizjak1, M T Haug, R J Schilz

  • 1College of Pharmacy, University of Arizona, USA.

Pharmacotherapy
|February 25, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants.

Transplant infectious disease : an official journal of the Transplantation Society·2003
Same author

The humoral immune response to influenza vaccination in lung transplant patients.

The European respiratory journal·2002
Same author

Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients.

Clinical transplantation·2001
Same author

Hypogammaglobulinemia in lung transplant recipients.

Transplantation·2001
Same author

Cystic fibrosis patients with and without central nervous system complications following lung transplantation.

Pediatric pulmonology·2000
Same author

Persistent left superior vena cava: case report and literature review.

Respiratory care·2000
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

High-dose intravenous azithromycin, used for pneumonia, may cause hearing loss. A patient developed complete deafness after 8 days of this antibiotic treatment, highlighting ototoxicity risks.

Area of Science:

  • Otolaryngology
  • Infectious Diseases
  • Pharmacology

Background:

  • Intravenous azithromycin is a common treatment for hospitalized community-acquired pneumonia.
  • Macrolide antibiotics, including azithromycin, are known to cause ototoxicity, particularly at high serum concentrations.
  • Current intravenous dosing regimens may lead to higher azithromycin serum levels compared to oral administration.

Observation:

  • A case study details a 47-year-old woman treated with intravenous azithromycin for community-acquired pneumonia.
  • The patient received 8 days of intravenous azithromycin therapy.
  • Following treatment, the patient experienced complete deafness.

Findings:

  • The case suggests a potential link between intravenous azithromycin administration and severe ototoxicity.

Related Experiment Videos

  • High serum concentrations of azithromycin, achievable with intravenous dosing, may be a contributing factor to hearing loss.
  • This adverse event highlights a specific risk associated with current treatment protocols.

    • Implications:

    • Healthcare providers should be aware of the ototoxicity risk associated with intravenous azithromycin.
    • Further research is warranted to evaluate the safety and optimal dosing of intravenous azithromycin, especially in vulnerable patient populations.
    • Consideration of alternative antibiotic regimens or closer monitoring for hearing impairment may be necessary in patients receiving prolonged intravenous azithromycin therapy.